ArticleArchives of surgery (Chicago, Ill. : 1960)2011
Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection.
Article in Archives of surgery (Chicago, Ill. : 1960), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.
- ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.Neuroendocrinology · 2016Guideline
- Value of surgery in patients with negative imaging and sporadic Zollinger-Ellison syndrome.Annals of surgery · 2012Trial
- Primary Tumor Size and Tumor-Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine Tumor.Current oncology (Toronto, Ont.) · 2026Article
- Current Medical Controversies in Zollinger-Ellison Syndrome.Biomedicines · 2025Review
- Glucagonoma and Glucagonoma Syndrome: An Updated Review.Clinical endocrinology · 2025Review
- Novel Surgical Initiatives in Gastroenteropancreatic Neuroendocrine Tumours.Current oncology reports · 2025Review
- Integrating Deep Learning-Based Dose Distribution Prediction with Bayesian Networks for Decision Support in Radiotherapy for Upper Gastrointestinal Cancer.Cancer research and treatment · 2025Article
- Combination of vascular surgery with novel vascular targeting agents as cancer therapeutics.Frontiers in oncology · 2025Review
- "Vascular tuft sign" in neuroendocrine tumors of the pancreas.Histology and histopathology · 2024Article
- Long-Term Proton Pump Inhibitor-Acid Suppressive Treatment Can Cause Vitamin BInternational journal of molecular sciences · 2024Article
- The Origins of Stanford Oncovascular Surgery.Annals of surgical oncology · 2024Article
- Festschrift for Dr. Jeffrey A. Norton, 12-13 October 2023, Stanford, CA, USA.Annals of surgical oncology · 2024Article
- Jeff Norton and the Definition of 'Un'.Annals of surgical oncology · 2024Article
- Contemporary Approaches to the Surgical Management of Pancreatic Neuroendocrine Tumors.Cancers · 2024Review
- Breaking down tumor thrombus: Current strategies for medical management.Thrombosis research · 2023Review
- Calcifications and Cystic Morphology on Preoperative Imaging Predict Survival After Resection of Pancreatic Neuroendocrine Tumors.Annals of surgical oncology · 2023Article
- Values of debulking surgery for unresectable well-differentiated metastatic pancreatic neuroendocrine tumors: a comparative study.Gastroenterology report · 2023Article
- Induction therapy withEuropean journal of nuclear medicine and molecular imaging · 2022Article
- Surgical Indications and Outcomes of Resection for Pancreatic Neuroendocrine Tumors with Vascular Involvement.Cancers · 2022Review
- Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundSurgery for pancreatic endocrine tumors (PETs) with blood vessel involvement is controversial. HYPOTHESIS: Resection of PETs with major blood vessel involvement can be beneficial.
designThe combined databases of the National Institutes of Health and Stanford University hospitals were queried.
main outcome measuresOperation, pathologic condition, complications, and disease-free and overall survival.
resultsOf 273 patients with PETs, 46 (17%) had preoperative computed tomography evidence of major vascular involvement. The mean size for the primary PET was 5.0 cm. The involved major vessel was as follows: portal vein (n = 20), superior mesenteric vein or superior mesenteric artery (n = 16), inferior vena cava (n = 4), splenic vein (n = 4), and heart (n = 2). Forty-two of 46 patients had a PET removed: 12 (27%) primary only, 30 (68%) with lymph nodes, and 18 (41%) with liver metastases. PETs were removed by either enucleation (n = 7) or resection (n = 35). Resections included distal or subtotal pancreatectomy in 23, Whipple in 10, and total in 2. Eighteen patients had concomitant liver resection: 10 wedge resection and 8 anatomic resections. Nine patients had vascular reconstruction: each had reconstruction of the superior mesenteric vein and portal vein, and 1 had concomitant reconstruction of the superior mesenteric artery. There were no deaths, but 12 patients had complications. Eighteen patients (41%) were immediately disease free, and 5 recurred with follow-up, leaving 13 (30%) disease-free long term. The 10-year overall survival was 60%. Functional tumors were associated with a better overall survival (P < .001), and liver metastases decreased overall survival (P < .001).
conclusionThese findings suggest that surgical resection of PETs with vascular abutment/invasion and nodal or distant metastases is indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.